(VIANEWS) – The NASDAQ opens in less than one hour and Royalty Pharma‘s pre-market value is already 4.83% up.
Royalty Pharma’s last close was $31.90, 28.57% under its 52-week high of $44.66.
The last session, NASDAQ ended with Royalty Pharma (RPRX) dropping 0.93% to $31.90. NASDAQ dropped 0.68% to $13,689.57, following the last session’s downward trend on what was a somewhat bearish trend trading session.
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Earnings Per Share
As for profitability, Royalty Pharma has a trailing twelve months EPS of $0.73.
PE Ratio
Royalty Pharma has a trailing twelve months price to earnings ratio of 43.7. Meaning, the purchaser of the share is investing $43.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.12%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 17, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 2.37%.
Moving Average
Royalty Pharma’s value is below its 50-day moving average of $34.71 and way below its 200-day moving average of $38.61.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Royalty Pharma’s EBITDA is 8.17.
More news about Royalty Pharma (RPRX).
